“Discover the Success of Novo Nordisk: Wegovy Sales Propel Better-Than-Expected Results”
Novo Nordisk’s Shares Rise After Strong Quarterly Results Overview Novo Nordisk’s U.S.-listed shares are up by 4% in premarket trading following the release of better-than-expected quarterly results. The company, known for its popular drugs Ozempic and Wegovy, managed to outperform projections despite facing challenges such as slower sales growth in 2025 due to increased competition…